Human adenovirus type 26 basic biology and its usage as vaccine vector

• Rab9 depletion enhances human adenovirus type 26 transduction efficiency through increased internalization and reduced late endosomal/lysosomal retention

  2026 PLoS Pathogens article Biochemistry, Genetics and Molecular Biology Virus-based gene therapy research Open access

  0

  citations
• Rab9 depletion enhances human adenovirus type 26 transduction efficiency through increased internalization and reduced late endosomal/lysosomal retention

  2026 bioRxiv (Cold Spring Harbor Laboratory) preprint Biochemistry, Genetics and Molecular Biology Virus-based gene therapy research Open access

  0

  citations

2 results

• Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine

  2021 New England Journal of Medicine article Medicine SARS-CoV-2 and COVID-19 Research Open access cited by 14 patents

  1,216

  citations
• Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques

  2020 Nature article Medicine SARS-CoV-2 and COVID-19 Research Open access cited by 38 patents

  797

  citations
• Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses

  2020 npj Vaccines article Medicine SARS-CoV-2 and COVID-19 Research Open access cited by 21 patents

  357

  citations
• Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans

  2021 Nature article Medicine SARS-CoV-2 and COVID-19 Research Open access cited by 2 patents

  314

  citations
• Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19

  2021 JAMA article Medicine SARS-CoV-2 and COVID-19 Research Open access cited by 2 patents

  305

  citations
• Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters

  2020 Nature Medicine article Medicine SARS-CoV-2 and COVID-19 Research Open access cited by 17 patents

  286

  citations
• Durable Humoral and Cellular Immune Responses 8 Months after Ad26.COV2.S Vaccination

  2021 New England Journal of Medicine article Medicine SARS-CoV-2 and COVID-19 Research Open access cited by 1 patent

  236

  citations
• Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial

  2020 The Lancet Infectious Diseases article Medicine Viral Infections and Outbreaks Research Open access cited by 7 patents

  173

  citations
• Thrombotic Thrombocytopenia after Ad26.COV2.S Vaccination — Response from the Manufacturer

  2021 New England Journal of Medicine article Medicine Heparin-Induced Thrombocytopenia and Thrombosis Open access

  119

  citations
• Phase 1 Safety and Immunogenicity Study of a Respiratory Syncytial Virus Vaccine With an Adenovirus 26 Vector Encoding Prefusion F (Ad26.RSV.preF) in Adults Aged ≥60 Years

  2020 The Journal of Infectious Diseases article Medicine Respiratory viral infections research cited by 9 patents

  111

  citations
• Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a study

  2020 The Lancet HIV article Immunology and Microbiology HIV Research and Treatment Open access cited by 3 patents

  88

  citations
• Prevention of Respiratory Syncytial Virus Infection in Healthy Adults by a Single Immunization of Ad26.RSV.preF in a Human Challenge Study

  2021 The Journal of Infectious Diseases article Medicine Respiratory viral infections research Open access

  88

  citations
• A Double-Blind, Randomized, Placebo-Controlled Phase 1 Study of Ad26.ZIKV.001, an Ad26-Vectored Anti–Zika Virus Vaccine

  2021 Annals of Internal Medicine article Medicine Mosquito-borne diseases and control

  80

  citations
• Human species D adenovirus hexon capsid protein mediates cell entry through a direct interaction with CD46

  2020 Proceedings of the National Academy of Sciences article Biochemistry, Genetics and Molecular Biology Virus-based gene therapy research Open access cited by 1 patent

  73

  citations
• Immunogenicity and efficacy of one and two doses of Ad26.COV2.S COVID vaccine in adult and aged NHP

  2021 The Journal of Experimental Medicine article Medicine SARS-CoV-2 and COVID-19 Research Open access cited by 6 patents

  71

  citations
• Low-dose Ad26.COV2.S protection against SARS-CoV-2 challenge in rhesus macaques

  2021 Cell article Medicine SARS-CoV-2 and COVID-19 Research Open access

  66

  citations
• Safety and Immunogenicity of the Ad26.RSV.preF Investigational Vaccine Coadministered With an Influenza Vaccine in Older Adults

  2020 The Journal of Infectious Diseases article Medicine Respiratory viral infections research Open access

  52

  citations
• Ad26-vector based COVID-19 vaccine encoding a prefusion stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses

  2020 bioRxiv (Cold Spring Harbor Laboratory) preprint Medicine SARS-CoV-2 and COVID-19 Research Open access cited by 21 patents

  45

  citations
• Ad26.COV2.S protects Syrian hamsters against G614 spike variant SARS-CoV-2 and does not enhance respiratory disease

  2021 npj Vaccines article Medicine SARS-CoV-2 and COVID-19 Research Open access cited by 18 patents

  45

  citations
• Safety and Immunogenicity of Heterologous and Homologous 2-Dose Regimens of Adenovirus Serotype 26– and Modified Vaccinia Ankara–Vectored Ebola Vaccines: A Randomized, Controlled Phase 1 Study

  2020 The Journal of Infectious Diseases article Medicine Viral Infections and Outbreaks Research Open access

  41

  citations